June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Netarsudil increases size of giant vacuoles in Schlemm’s canal of perfused human eyes
Author Affiliations & Notes
  • Kevin Wu
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Ruiyi Ren
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
    Anatomy and Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Guorong Li
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • Casey Kopczynski
    Research and Development, Aerie Pharmaceuticals, Inc, Research Triangle Park, North Carolina, United States
  • W Daniel Stamer
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • Haiyan Gong
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
    Anatomy and Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Kevin Wu, Aerie Pharmaceuticals, Inc (F); Ruiyi Ren, Aerie Pharmaceuticals, Inc (F); Guorong Li, Aerie Pharmaceuticals, Inc (F); Casey Kopczynski, Aerie Pharmaceuticals, Inc (E); W Daniel Stamer, Aerie Pharmaceuticals, Inc (F); Haiyan Gong, Aerie Pharmaceuticals, Inc (F)
  • Footnotes
    Support  National Institute of Health Grant EY022634 and EY019696, Aerie Pharmaceuticals Inc, The Massachusetts Lions Eye Research Fund
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1074. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kevin Wu, Ruiyi Ren, Guorong Li, Casey Kopczynski, W Daniel Stamer, Haiyan Gong; Netarsudil increases size of giant vacuoles in Schlemm’s canal of perfused human eyes. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1074.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Phase 3 clinical trials of Netarsudil, an inhibitor of Rho kinase/norepinephrine transporter, have shown promising results as a potential new treatment for glaucoma. Netarsudil lowers intraocular pressure primarily by increasing trabecular outflow facility; however, the mechanisms by which outflow facility is increased have yet to be fully elucidated. This study tested the hypothesis that one mechanism by which Netarsudil increases outflow facility is through its effects on giant vacuole (GV) formation along the inner wall of Schlemm’s Canal (SC).

Methods : Five pairs of normal human eyes were perfused with phosphate buffered saline containing 5.5mM glucose (GPBS) at 15 mmHg to establish a stable baseline. One eye of each pair was then exchanged (5mL) and perfused with 0.3μM Netarsudil-M1, the active metabolite of Netarsudil, for 3 hours, while the contralateral eye was treated with vehicle in GPBS. After tracer labeling of the outflow pattern, perfusion-fixation and sample processing, 2μm frontal sections were obtained from high and low tracer regions of each eye. Light microscope images were taken using a 40x objective along the inner wall of SC. ImageJ was used to measure the density and cross-sectional area (size) for each GV. Student T-test, nonparametric Mann-Whitney U test, linear regression and chi square test were performed with a required significance of p < 0.05.

Results : A total of 2787 GVs were analyzed between the controls (1554 GVs) and Netarsudil treated eyes (1233 GVs). No significant difference in density of GVs was found between untreated and treated eyes (p=0.22). The average size of GVs in Netarsudil treated eyes (15.2 ± 1.3μm2) were significantly larger than in control eyes (11.0±1.3μm2, p<0.05). The percentage of GV ≥35μm2 (the size required for pore formation by another study in the lab) is significantly increased after Netarsudil treatment (9.89% vs. 5.60%, p<0.001). There is a significant positive correlation between GV size and percentage change in outflow facility (p=0.02).

Conclusions : Our results suggest that one of the mechanisms by which Netarsudil increases outflow facility is through increasing the size of GVs, especially the prevalence of GVs ≥ 35μm2. This is the first time a drug-induced change in SC has been directly correlated with an increase in outflow facility.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×